Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation

. Author manuscript; available in PMC: 2024 Jan 27.

Published in final edited form as: Stem Cell Res. 2023 Sep 27;72:103215. doi: 10.1016/j.scr.2023.103215

Resource table

Unique stem cell line identifier	1. SCVIi066-A 2. SCVIi067-A
Alternative name(s) of stem cell line	1. N/A 2. N/A
Institution	Stanford Cardiovascular Institute, Stanford, CA, USA
Contact information of distribution	Joseph C. Wu; joewu@stanford.edu
Type of cell lines	Induced pluripotent stem cells (iPSCs)
Origin	Human
Additional origin info required	Age: 65 years old (SCVIi066-A) and 63 years old (SCVIi067-A). Sex: Male (both). Ethnicity: Caucasian (both).
Cell source	Peripheral blood mononuclear cells (PBMCs)
Clonality	Clonal
Method of reprogramming	Sendai virus vectors
Genetic Modification	Yes
Type of genetic modification	Spontaneous mutation
Evidence of reprogramming	RT-qPCR / Immunofluorescence
Associated disease	Transthyretin Amyloidosis
Gene/locus	TTR (18q12.1) SCVIi066-A: heterozygous TTR (c.148G>A) SCVIi067-A: heterozygous TTR (c.148G>A)
Date archived/stock date	SCVIi066-A (11/11/2019) SCVIi067-A (09/21/2022)
Cell line repository/biobank	https://hpscreg.eu/cell-line/SCVIi066-A https://hpscreg.eu/cell-line/SCVIi067-A
Ethical Approval	The generation of the line was approved by the Administrative Panel on Human Subjects Research (IRB) under IRB #29904 “Derivation of Human Induced Pluripotent Stem Cells (Biorepository)”.